Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Clinical Trials Using IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

Review the clinical trials studying il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-1 of 1

Chemotherapy and CAR-T Cell Immunotherapy (Brain Tumor‐Specific Immune Cells) for the Treatment of IL13Ralpha2 Positive Recurrent or Refractory Brain Tumors or Newly Diagnosed DIPG/DMG
Status: Active
Location: 3 locations